



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Harrington, et al.

Serial No.: 08/951,733

Group Art Unit No.: 1634

Filed: October 16, 1997

Examiner: N/A

For: Novel Genes Encoding Telomerase Proteins

Docket No.: A-433B

RECEIVED

JUN 23 1998

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of each reference listed on the attached supplemental PTO-1449 (Modified) form for consideration by the Examiner. The original Japanese version of each document is enclosed together with an English translation.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen, Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Nancy A. Oleski
Attorney/Agent for Applicants
Registration No.: 34,688
Phone: (805) 447-6504
Date: June 17, 1998

Please send all future correspondence to:
U.S. Patent Operations/NAO
Dept. 430, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1789

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number: TB813597631 US

Date of Deposit: June 18, 1998

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

F. Craft

Printed Name

Signature